New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:18 EDTMYLMylan announces agreement with Biocon for collaboration on insulin products
Mylan (MYL) announced that it has entered into a definitive agreement with Biocon Limited for an exclusive strategic collaboration on the development and commercialization of generic versions of three insulin analog products. Under the terms of this collaboration, Mylan will have the rights to develop and market Biocon's Glargine, the generic version of Sanofi's (SNY) Lantus, Lispro, the generic version of Eli Lilly's (LLY) Humalog, and Aspart, the generic version of Novo Nordisk's (NVO) NovoLog. Mylan and Biocon will share development, capital and certain other costs to bring the products to market. Reported worldwide net sales of Lantus, Humalog and NovoLog for 2012 were approximately $11.5B.
News For MYL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent MYL news | >>
April 9, 2015
05:49 EDTMYLStocks with implied volatility movement; MYL TEVA
Subscribe for More Information
April 8, 2015
16:22 EDTMYLOn The Fly: Closing Wrap
Subscribe for More Information
16:01 EDTMYLActionable Options for Wednesday, April, 8
Subscribe for More Information
15:27 EDTMYLMylan hasn't made compelling case for Perrigo adding value, says BMO Capital
Subscribe for More Information
15:16 EDTMYLPerrigo not likely interested in a Mylan deal, says BMO Capital
14:23 EDTMYLAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
13:07 EDTMYLMylan bid for Perrigo makes strategic sense, says JPMorgan
Subscribe for More Information
13:03 EDTMYLPerrigo says board will meet to discuss Mylan proposal
Subscribe for More Information
12:17 EDTMYLOn The Fly: Midday Wrap
Subscribe for More Information
11:51 EDTMYLPerrigo calls active on Mylan proposal to acquire for $205 per share
Subscribe for More Information
11:45 EDTMYLMylan volatility up after proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:40 EDTMYLPerrigo up $47.10 to $211.81, trading above Mylan's $205/share proposal
Subscribe for More Information
11:35 EDTMYLGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
Subscribe for More Information
11:34 EDTMYLGeneric drug maker Akorn up 4% to $49.80 after Myla offers to buy Perrigo
11:32 EDTMYLMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
11:31 EDTMYLPerrigo halted for volatility after jumping 7% to $176.42
Subscribe for More Information
11:29 EDTMYLMylan proposes to acquire Perrigo for $205 per share
Subscribe for More Information
07:16 EDTMYLMylan one of the cheapest names in Specialty Pharma, says JPMorgan
Subscribe for More Information
April 7, 2015
10:19 EDTMYLHigh option volume stocks
Subscribe for More Information
07:32 EDTMYLMylan launches Norethindrone and Ethinyl Estradiol Tablets in U.S.
Subscribe for More Information
1 | 2 | 3 | all recent MYL news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use